NRX Pharmaceuticals (NRXP) Return on Sales (2025 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly Return on Sales came in at 0.05% in Q1 2026, up 3.5% on a QoQ basis from 0.05% in Q4 2025.
NRX Pharmaceuticals (NRXP) Return on Sales (2025 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 2 years of Return on Sales data on file, last reported at 0.05% in Q1 2026.
- On a quarterly basis, Return on Sales changed N/A year-over-year to 0.05% in Q1 2026; TTM through Mar 2026 was 0.08%, a N/A change from a year earlier, with the FY2025 full-year figure at 0.56%, changed N/A from the prior year.
- Return on Sales for Q1 2026 stood at 0.05%, up from 0.05% in the prior quarter.
- Over the last five years, Return on Sales for NRXP reached as high as 0.05% in Q1 2026 and fell as low as 0.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 0.00% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | NRX Pharmaceuticals | 137.57 Mn | 130.87 Mn | 437,000.00 | -0.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.05% |
| Dec 31, 2025 | -0.05% |
| Sep 30, 2025 | -0.21% |